How to use YTTRIGA PRECURSOR RADIOFARMACEUTICO EN SOLUCION - Radiopharmaceutical precursor in solution
Translated with AI
This page provides general information and does not replace a doctor’s consultation. Always consult a doctor before taking any medication. Seek urgent medical care if symptoms are severe.
Show originalContents of the leaflet
Introduction
PACKAGE LEAFLET: INFORMATION FOR THE USER
Yttriga radiopharmaceutical precursor in solution.
Chloride of (90Y) yttrium
Read all of this leaflet carefully before you start using this medicine.
- Keep this leaflet. You may need to read it again.
- If you have any further questions, ask your doctor or pharmacist.
- If you experience any side effects, talk to your doctor or pharmacist. This includes any possible side effects not listed in this leaflet. See section 4.
In this leaflet:
- What is Yttriga and what is it used for
- Before you use Yttriga
- How to use Yttriga
- Possible side effects
- Storage of Yttriga
- Further information
1. What is YTTRIGA and what is it used for
Yttriga is a radioactive medicinal product used in combination with another medicinal product that targets specific cells in the body.
When the target is reached, Yttriga provides tiny doses of radiation to these specific sites.
For more information about the treatment and possible effects caused by the radiolabelled medicinal product, see the package leaflet of the medicinal product used in combination.
2. Before you use YTTRIGA
Do not use Yttriga:
- if you are allergic (hypersensitive) to chloride of (90Y) yttrium or any of the other components of Yttriga.
- if you are pregnant or if there is a possibility that you may be pregnant (see below).
Take special care with Yttriga:
Yttriga is a radioactive medicinal product and is only used in combination with another medicinal product.
Its intended use is not direct administration to patients.
Due to strict laws regarding the use, handling, and disposal of radiopharmaceuticals, this product must be used exclusively in a hospital or similar facility. It must be handled and administered exclusively by qualified and trained personnel for the safe treatment of radioactive materials.
Special care should be taken when administering radioactive medicinal products to children and adolescents (from 2 to 16 years of age).
Use of other medicinal products
Tell your doctor or pharmacist if you are using or have recently used any other medicinal products, including those obtained without a prescription.
The interaction of chloride of (90Y) yttrium with other medicinal products is unknown, as no clinical studies are available.
Pregnancy
Yttriga is contraindicated in pregnancy.
Tell your doctor if there is any possibility that you may be pregnant. If you experience a delay in your menstrual period, you should assume you are pregnant until proven otherwise.
Your doctor will consider the possibility of using alternative techniques that do not involve the use of ionizing radiation.
Women of childbearing age must use effective contraceptive methods during and after treatment.
Breast-feeding
Your doctor will ask you to interrupt breast-feeding.
Ask your doctor or pharmacist for advice before taking any medicinal product.
3. How to use YTTRIGA
Your doctor will not administer Yttriga directly.
Dose.
Your doctor will decide what quantity of Yttriga you will receive for treatment.
Method of administration
YTTRIGA is a radioactive medicinal product used in combination with another medicinal product that targets specific cells in the body and is administered by your doctor.
If Yttriga is administered inadvertently
Yttriga is administered by your doctor after combining it with another medicinal product under strictly controlled conditions. The risk of receiving a possible overdose is small. However, if this occurs, you will receive appropriate treatment from your doctor.
4. Possible side effects
Like all medicinal products, Yttriga can cause side effects, although not everybody gets them.
For more information, see the package leaflet of the specific medicinal product that will be radiolabelled.
If you experience any side effect not mentioned in this leaflet or if you experience any of the side effects described as severe, tell your doctor or pharmacist.
Reporting of side effects
If you experience any side effects, talk to your doctor or pharmacist. This includes any possible side effects not listed in this leaflet. You can also report side effects directly via the national reporting system listed in Appendix V. By reporting side effects, you can help provide more information on the safety of this medicinal product.
5. Storage of YTTRIGA
Keep out of the reach and sight of children.
Do not use Yttriga after the expiry date stated on the label after EXP.
Storage must be carried out in accordance with local regulations for radioactive substances.
Disposal of unused medicinal product and all materials that have come into contact with it will be carried out in accordance with local regulations.
6. FURTHER INFORMATION
What contains Yttriga?
- The active substance is chloride of (90Y) yttrium.
- 1 ml of sterile solution contains 0.1-300 GBq of (90Y) yttrium on the reference date and time (equivalent to 0.005-15 micrograms of (90Y) yttrium) (as chloride of (90Y) yttrium).
- The other components are hydrochloric acid (0.04 M).
Appearance and packaging of Yttriga
Colourless glass type I vial of 3 ml with a V-shaped bottom or a colourless glass type I vial with a flat bottom of 10 ml with a silicone plug, sealed with an aluminium seal.
Radiopharmaceutical precursor in solution.
Transparent and colourless sterile solution
Marketing authorisation holder
Eckert & Ziegler Radiopharma GmbH
Robert-Rössle-Str. 10
D-13125 Berlin
Germany
Tel +49- 30-941084-280
Fax +49- 30-941084-470
e-mail: [email protected]
Manufacturer
Eckert & Ziegler Radiopharma GmbH
Branch Braunschweig
Gieselweg 1
D-38110 Braunschweig
Germany
You can obtain further information on this medicinal product from the representative of the marketing authorisation holder in your country:
Belgium Eckert & Ziegler Radiopharma GmbH Robert-Rössle-Straße 10 D-13125 Berlin Tel: +49-30-941084-280 | Lithuania Eckert & Ziegler Radiopharma GmbH Robert-Rössle-Straße 10 D-13125 Berlin Tel: +49-30-941084-280 |
Bulgaria Eckert & Ziegler Radiopharma GmbH Robert-Rössle-Straße 10 D-13125 Berlin Tel: +49-30-941084-280 | Luxembourg Eckert & Ziegler Radiopharma GmbH Robert-Rössle-Straße 10 D-13125 Berlin Tel: +49-30-941084-280 |
Czech Republic Eckert & Ziegler Radiopharma GmbH Robert-Rössle-Straße 10 D-13125 Berlin Tel: +49-30-941084-280 | Hungary Eckert & Ziegler Radiopharma GmbH Robert-Rössle-Straße 10 D-13125 Berlin Tel: +49-30-941084-280 |
Denmark Eckert & Ziegler Radiopharma GmbH Robert-Rössle-Straße 10 D-13125 Berlin Tel: +49-30-941084-280 | Malta Eckert & Ziegler Radiopharma GmbH Robert-Rössle-Straße 10 D-13125 Berlin Tel: +49-30-941084-280 |
Germany Eckert & Ziegler Radiopharma GmbH Robert-Rössle-Straße 10 D-13125 Berlin Tel: +49-30-941084-280 | Netherlands Eckert & Ziegler Radiopharma GmbH Robert-Rössle-Straße 10 D-13125 Berlin Tel: +49-30-941084-280 |
Estonia Eckert & Ziegler Radiopharma GmbH Robert-Rössle-Straße 10 D-13125 Berlin Tel: +49-30-941084-280 | Norway Eckert & Ziegler Radiopharma GmbH Robert-Rössle-Straße 10 D-13125 Berlin Tel: +49-30-941084-280 |
Greece Eckert & Ziegler Radiopharma GmbH Robert-Rössle-Straße 10 D-13125 Berlin Tel: +49-30-941084-280 | Austria Eckert & Ziegler Radiopharma GmbH Robert-Rössle-Straße 10 D-13125 Berlin Tel: +49-30-941084-280 |
Spain NUCLIBER, S.A. C/ Hierro, 33 E-28045 Madrid Tel: +34 915 062 940 | Poland Eckert & Ziegler Radiopharma GmbH Robert-Rössle-Straße 10 D-13125 Berlin Tel: +49-30-941084-280 |
France Eckert & Ziegler Radiopharma GmbH Robert-Rössle-Straße 10 D-13125 Berlin Tel: +49-30-941084-280 | Portugal Eckert & Ziegler Radiopharma GmbH Robert-Rössle-Straße 10 D-13125 Berlin Tel: +49-30-941084-280 |
Croatia Eckert & Ziegler Radiopharma GmbH Robert-Rössle-Straße 10 D-13125 Berlin Tel: +49-30-941084-280 | Romania Eckert & Ziegler Radiopharma GmbH Robert-Rössle-Straße 10 D-13125 Berlin Tel: +49-30-941084-280 |
Ireland Advanced Accelerator Applications (UK & Ireland) Ltd. Edison House, 223-231 Old Marylebone Road, London, NW1 5QT – UK Tel: +44 (0)2072585252 | Slovenia Eckert & Ziegler Radiopharma GmbH Robert-Rössle-Straße 10 D-13125 Berlin Tel: +49-30-941084-280 |
Iceland Eckert & Ziegler Radiopharma GmbH Robert-Rössle-Straße 10 D-13125 Berlin Tel: +49-30-941084-280 | Slovak Republic Eckert & Ziegler Radiopharma GmbH Robert-Rössle-Straße 10 D-13125 Berlin Tel: +49-30-941084-280 |
Italy Campoverde srl Via Quintiliano, 30 I-20138 Milano Tel: +39-02-58039045 | Finland Eckert & Ziegler Radiopharma GmbH Robert-Rössle-Straße 10 D-13125 Berlin Tel: +49-30-941084-280 |
Cyprus Eckert & Ziegler Radiopharma GmbH Robert-Rössle-Straße 10 D-13125 Berlin Tel: +49-30-941084-280 | Sweden Eckert & Ziegler Radiopharma GmbH Robert-Rössle-Straße 10 D-13125 Berlin Tel: +49-30-941084-280 |
Latvia Eckert & Ziegler Radiopharma GmbH Robert-Rössle-Straße 10 D-13125 Berlin Tel: +49-30-941084-280 | United Kingdom Advanced Accelerator Applications (UK & Ireland) Ltd. Edison House, 223-231 Old Marylebone Road, London, NW1 5QT – UK Tel: +44 (0)2072585252 |
Date of last revision of this leaflet:{MM/YYYY}.
Other sources of information
Detailed information on this medicinal product is available on the European Medicines Agency website: http://www.ema.europa.eu.
The leaflet can be found in all languages of the European Union/European Economic Area on the European Medicines Agency website.
.
-
- Country of registration
- Dosage formRADIOPHARMACEUTICAL, 0.005-15 mcg
- Prescription requiredYes
- Manufacturer
- This information is for reference only and does not constitute medical advice. Always consult a doctor before taking any medication. Oladoctor is not responsible for medical decisions based on this content.
- Alternatives to YTTRIGA PRECURSOR RADIOFARMACEUTICO EN SOLUCION - Radiopharmaceutical precursor in solutionDosage form: INJECTABLE PERFUSION, 370 MBq/mlActive substance: lutetium (177Lu) oxodotreotideManufacturer: Advanced Accelerator ApplicationsPrescription requiredDosage form: INJECTABLE, 1 000 MBq/mlActive substance: lutetium (177Lu) vipivotide tetraxetanManufacturer: Novartis Europharm LimitedPrescription requiredDosage form: INJECTABLE, 1000 kBq/ml at reference dateActive substance: radium (223Ra) dichlorideManufacturer: Bayer AgPrescription required
Online doctors for YTTRIGA PRECURSOR RADIOFARMACEUTICO EN SOLUCION - Radiopharmaceutical precursor in solution
Discuss questions about YTTRIGA PRECURSOR RADIOFARMACEUTICO EN SOLUCION - Radiopharmaceutical precursor in solution, including use, safety considerations and prescription review, subject to medical assessment and local regulations.
Get YTTRIGA PRECURSOR RADIOFARMACEUTICO EN SOLUCION - Radiopharmaceutical precursor in solution Prescription Online
Fill in a 2-min form
Tell us your symptoms, history, and what medicine you're requesting.
Pick a doctor or let us assign
Choose a specialist or we'll match you with the next available doctor.
Doctor reviews your case
Usually within 30 minutes. They may ask follow-up questions via chat.
Collect from any pharmacy
Electronic prescription sent to your email — valid across Spain.
Frequently Asked Questions
YTTRIGA PRECURSOR RADIOFARMACEUTICO EN SOLUCION - Radiopharmaceutical precursor in solution requires a prescription in Spain. You can check with a doctor online whether this medicine may be appropriate for your situation.
YTTRIGA PRECURSOR RADIOFARMACEUTICO EN SOLUCION - Radiopharmaceutical precursor in solution is manufactured by Eckert & Ziegler Radiopharma Gmbh. Pharmacy brands and packaging may differ depending on the distributor.
Doctors such as Family doctors, Psychiatrists, Dermatologists, Cardiologists, Endocrinologists, Gastroenterologists, Pulmonologists, Nephrologists, Rheumatologists, Hematologists, Infectious disease physicians, Allergists, Geriatricians, Paediatricians, Oncologists may assess whether YTTRIGA PRECURSOR RADIOFARMACEUTICO EN SOLUCION - Radiopharmaceutical precursor in solution is appropriate, depending on your situation and local regulations. You can book an online consultation to discuss your symptoms and possible next steps.
Spain has a well-developed healthcare infrastructure across major cities such as Madrid, Barcelona, Valencia, and Seville. Pharmacies are widely available and operate under strict regulations, ensuring access to prescribed medications.
You can buy YTTRIGA PRECURSOR RADIOFARMACEUTICO EN SOLUCION - Radiopharmaceutical precursor in solution in Madrid, Barcelona, Seville, or Valencia at any local pharmacy with a valid prescription.
To obtain a prescription, you can use Oladoctor:
Other medicines with the same active substance () include LUTATHERA 370 MBq/mL SOLUTION FOR INFUSION, PLUVICTO 1000 MBq/mL Injectable Solution and Perfusion Solution, Xofigo 1100 kBq/ml injectable solution. These may have different brand names or formulations but contain the same therapeutic ingredient. Always consult a doctor before switching or starting a new medicine.